Dacogen

Product manufactured by Eisai Inc.

Application Nr Approved Date Route Status External Links
NDA021790 2006-05-02 Intravenous RX Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Dacogen Is Indicated For Treatment Of Patients With Myelodysplastic Syndromes (mds) Including Previously Treated And Untreated, De Novo And Secondary Mds Of All French-American-British Subtypes (refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts In Transformation, And Chronic Myelomonocytic Leukemia) And Intermediate-1, Intermediate-2, And High-Risk International Prognostic Scoring System Groups. Dacogen Is A Nucleoside Metabolic Inhibitor Indicated For Treatment Of Patients With Myelodysplastic Syndromes (mds) Including Previously Treated And Untreated, De Novo And Secondary Mds Of All French-American-British Subtypes (refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts In Transformation, And Chronic Myelomonocytic Leukemia) And Intermediate-1, Intermediate-2, And High-Risk International Prognostic Scoring System Groups. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Decitabine DECITABINE ZINC16929327

Comments